Brief Article
Copyright ©2013 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. Sep 14, 2013; 19(34): 5665-5670
Published online Sep 14, 2013. doi: 10.3748/wjg.v19.i34.5665
5-ASA colonic mucosal concentrations resulting from different pharmaceutical formulations in ulcerative colitis
Renata D’Incà, Martina Paccagnella, Romilda Cardin, Surajit Pathak, Vincenzo Baldo, Maria Cecilia Giron, Giacomo Carlo Sturniolo
Renata D’Incà, Martina Paccagnella, Romilda Cardin, Surajit Pathak, Giacomo Carlo Sturniolo, Department of Surgical, Oncological and Gastroenterological Sciences, University of Padua, 35127 Padova, Italy
Vincenzo Baldo, Department of Environmental Medicine and Public Health, Institute of Hygiene, University of Padua, 35127 Padova, Italy
Maria Cecilia Giron, Department of Pharmacology and Anaesthesiology, University of Florence, 50121 Florence, Italy
Author contributions: D’Incà R co-ordinated the study and wrote the manuscript; Paccagnella M collected the human material and made the first draft of the manuscript; Cardin R performed the majority of the experiments; Pathak S revised the paper; Baldo V analysed the data; Giron MC provided criticisms and suggestions; Sturniolo GC designed the study.
Correspondence to: Dr. Renata D’Incà, Division of Gastroenterology, Department of Surgical, Oncological and Gastroenterological Sciences, VI piano Monoblocco, Via Giustiniani 2, 35127 Padova, Italy. dinca@unipd.it
Telephone: +39-49-8212893 Fax: +39-49-8760820
Received: February 22, 2013
Revised: May 9, 2013
Accepted: May 18, 2013
Published online: September 14, 2013
Processing time: 203 Days and 19.1 Hours
Core Tip

Core tip: We report on the concentrations of 5-aminosalicylic acid in the colonic mucosa of ulcerative colitis patients. Significant variations in concentration were observed that were dependent on the type of pharmaceutical formulation and the presence of active disease. Combined oral and topical therapy yielded higher tissue mesalamine concentrations. These differences should be taken into account in treatment strategies, especially in view of the fact that mesalamine can induce mucosal healing in ulcerative colitis.